The US/China Trade Agreement: what could it mean for the Pharma Industry?

Following a long period of negotiation, Phase I of the US-China Trade Agreement was published on 15 January 2020. An important element of the negotiations from the US side had focussed on the need for China to recognise and strengthen the protection of intellectual property (IP) rights held by US companies in China. Chapter 1 of the Agreement is of particular relevance to pharmaceutical companies as it contains a broad range of measures that, if implemented into law and properly enforced, could have a significant beneficial effect for IP rights owners in China.

Latest insights

More Insights
featured image

Employment Litigation in Singapore: Employees Can Double-Strike with Employment Claims Tribunal Win Followed by High Court Claim

4 minutes Jul 11 2025

Read More
Curiosity line yellow background

Sprinting to an IPO? ASIC trials a streamlined fast-track to the ASX

Jul 08 2025

Read More
featured image

EPO Upholds, UPC Revokes: A Tale of Diverging Views on PCSK9 Antibody Patent

2 minutes Jul 02 2025

Read More